Salix Pharmaceuticals plans to boost its business by selling $50 million in convertible notes to institutional buyers, the Raleigh drug maker said Monday. Salix says it will use the cash from the offering to fund potential product acquisitions or in-licensing opportunities. Money also will be used to develop experimental drugs and for general corporate purposes, the company said in a statement.
